Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212980 | 0.87 | CYP11B1 (0.50) | CYP11B1CYP11B2F2POLBALDH1A1 | |
| SCHEMBL19212929 | 0.85 | CYP11B1 (0.62) | CYP11B1CYP11B2ALDH1A1KMT2A | |
| SCHEMBL19212943 | 0.85 | CYP11B1 (0.65) | CYP11B1CYP11B2F2POLBALDH1A1 | |
| SCHEMBL19212925 | 0.82 | CYP11B1 (0.49) | CYP11B1CYP11B2F2POLBALDH1A1 | |
| SCHEMBL17723947 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL19212911 | 0.75 | CES2 (0.53) | CYP11B1CYP11B2ALDH1A1KMT2A | |
| SCHEMBL19212982 | 0.74 | CYP11B1 (0.65) | CYP11B1CYP11B2F2ALDH1A1KMT2A | |
| SCHEMBL19212999 | 0.74 | CYP11B1 (0.60) | CYP11B1CYP11B2ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL16604316 | 0.74 | ALDH1A1 (0.61) | CYP11B1CYP11B2F2POLBALDH1A1 | |
| SCHEMBL19212981 | 0.72 | CYP11B1 (0.67) | CYP11B1CYP11B2POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | PDXK, PNPO, PAH | CYP11B1 84/4885CYP11B2 32/4885F2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.